Ivabradine Accord-Uk (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a lower resting heart rate without decreasing the strength of heart contractions.

The dose of Ivabradine Accord-Uk is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerance. The prescriber determines the appropriate strength and dosing schedule for each patient.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s profile.

Ivabradine Accord-Uk should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ivabradine Accord-Uk is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may be persistent. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, acute myocardial infarction, unstable angina, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with a resting heart rate below 50 bpm unless closely supervised.